EP1093367A4 - Proteaseinhibitoren - Google Patents

Proteaseinhibitoren

Info

Publication number
EP1093367A4
EP1093367A4 EP99930779A EP99930779A EP1093367A4 EP 1093367 A4 EP1093367 A4 EP 1093367A4 EP 99930779 A EP99930779 A EP 99930779A EP 99930779 A EP99930779 A EP 99930779A EP 1093367 A4 EP1093367 A4 EP 1093367A4
Authority
EP
European Patent Office
Prior art keywords
protease inhibitors
protease
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99930779A
Other languages
English (en)
French (fr)
Other versions
EP1093367A1 (de
Inventor
Stacie Marie Halbert
Evelyne Michaud
Scott Kevin Thompson
Daniel Frank Veber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1093367A1 publication Critical patent/EP1093367A1/de
Publication of EP1093367A4 publication Critical patent/EP1093367A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP99930779A 1998-06-24 1999-06-24 Proteaseinhibitoren Withdrawn EP1093367A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9049398P 1998-06-24 1998-06-24
US90493P 1998-06-24
PCT/US1999/014561 WO1999066925A1 (en) 1998-06-24 1999-06-24 Protease inhibitors

Publications (2)

Publication Number Publication Date
EP1093367A1 EP1093367A1 (de) 2001-04-25
EP1093367A4 true EP1093367A4 (de) 2003-03-05

Family

ID=22223011

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99930779A Withdrawn EP1093367A4 (de) 1998-06-24 1999-06-24 Proteaseinhibitoren

Country Status (6)

Country Link
EP (1) EP1093367A4 (de)
JP (1) JP2002518444A (de)
AR (1) AR018915A1 (de)
AU (1) AU4723799A (de)
CA (1) CA2335876A1 (de)
WO (1) WO1999066925A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2001034600A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
AU1588901A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
JP2003513924A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
OA12323A (en) 2000-03-21 2006-05-15 Smithkline Beecham Corp Protease inhibitors.
US7282512B2 (en) 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
US7273866B2 (en) 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
JP4851337B2 (ja) * 2003-11-10 2012-01-11 シンタ ファーマシューティカルズ コーポレーション ヘテロアリールヒドラゾン化合物
CL2007003879A1 (es) * 2006-12-29 2008-07-04 Basf Ag Compuestos derivados de aril-carboxamida; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como alzheimer, epilepsia y parkinson.
TWI453019B (zh) * 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物
CN102408387A (zh) * 2010-09-26 2012-04-11 韩南银 一种具有抗肿瘤作用的金属络合物
KR20150046259A (ko) 2012-08-23 2015-04-29 앨리오스 바이오파마 인크. 파라믹소바이러스 바이러스성 감염의 치료용 화합물
CN103113300A (zh) * 2013-03-06 2013-05-22 广西中医药大学 一种具有抗肿瘤活性的化合物的制备方法和用途
WO2014179943A1 (zh) * 2013-05-08 2014-11-13 Yang Yongliang 一种马来酰胺化合物、其制备方法及其用途
CN103242321A (zh) * 2013-05-21 2013-08-14 苏州科捷生物医药有限公司 苄基哌嗪类化合物及其抗肿瘤用途
CA2921294C (en) 2013-08-21 2023-05-16 Alios Biopharma, Inc. Antiviral compounds
CN103880703B (zh) * 2014-03-14 2016-04-13 浙江工业大学 O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗人胎盘绒毛癌药物中的应用
CN103880702B (zh) * 2014-03-14 2016-04-13 浙江工业大学 O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗白血病药物中的应用
CN103880701B (zh) * 2014-03-14 2016-04-13 浙江工业大学 O-肉桂酰-氟苯水杨酰胺类化合物及其在制备抗人宫颈鳞状癌药物中的应用
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK56798A3 (en) * 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9966925A1 *

Also Published As

Publication number Publication date
WO1999066925A1 (en) 1999-12-29
CA2335876A1 (en) 1999-12-29
JP2002518444A (ja) 2002-06-25
EP1093367A1 (de) 2001-04-25
AR018915A1 (es) 2001-12-12
AU4723799A (en) 2000-01-10

Similar Documents

Publication Publication Date Title
PL349192A1 (en) Protease inhibitors
IL131661A0 (en) Protease inhibitors
PL336589A1 (en) Serinic protease inhibitors
PL337755A1 (en) Protease inhibitors
IL132629A0 (en) Protease inhibitors
PL336856A1 (en) Protease inhibitors
AU4723799A (en) Protease inhibitors
ZA988479B (en) Protease inhibitors
EP1067894A4 (de) Protheaseinhibitoren
IL139187A0 (en) Cysteine protease inhibitors
EP1079821A4 (de) Protease inhibitoren
EP1235577A4 (de) Proteaseinhibitoren
GB9800817D0 (en) Serine protease inhibitors
AU1393900A (en) Morpholino-ethoxybenzofuran protease inhibitors
EP1232155A4 (de) Protease inhibitoren
EP1140897A4 (de) Protease inhibitoren
EP1086083A4 (de) Proteaseinhibitoren
ZA988064B (en) Protease inhibitors
EP1231921A4 (de) Proteaseinhibitoren
EP1229914A4 (de) Proteasehemmer
EP1229912A4 (de) Proteaseinhibitoren
EP1229915A4 (de) Proteasehemmer
EP1351930A4 (de) Protease inhibitoren
EP1161237A4 (de) Protease-inhibitoren
EP1233771A4 (de) Proteasehemmer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20030122

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030410